Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 5, 2016, Pages

  Palmer, Suetonia C ^a   Natale, Patrizia ^b   Ruospo, Marinella ^b,c   Saglimbene, Valeria M ^b   Rabindranath, Kannaiyan S ^d   Craig, Jonathan C ^e,f   Strippoli, Giovanni F M ^b,f,g,h  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Diaverum   (Sweden)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d Orthopaedic Department   (New Zealand)

^e UNIVERSITY OF SYDNEY   (Australia)

^f University of Sydney   (Australia)

^g UNIVERSITY OF BARI   (Italy)

^h Diaverum Academy   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; LOFEPRAMINE; MALEIC ACID; MAPROTILINE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; REBOXETINE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; VENLAFAXINE;

ADULT; ADVERSE OUTCOME; CLINICAL EVALUATION; COCHRANE LIBRARY; COMPARATIVE STUDY; DEPRESSION; DIALYSIS; DIZZINESS; DRUG EFFECT; END STAGE RENAL DISEASE; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HEADACHE; HOSPITALIZATION; HUMAN; HYPOTENSION; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PATIENT HARM; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SEXUAL DYSFUNCTION; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL; KIDNEY FAILURE, CHRONIC; META ANALYSIS; PSYCHOLOGY; RENAL REPLACEMENT THERAPY;

ADULT; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSION; FLUOXETINE; HUMANS; KIDNEY FAILURE, CHRONIC; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; SERTRALINE;

EID: 84969498060     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004541.pub3     Document Type: Review

References (209)

1. Blumenfield M, Levy NB, Spinowitz B, Charytan C, Beasley CM Jr, Dubey AK, et al. Fluoxetine in depressed patients on dialysis. International Journal of Psychiatry in Medicine 1997;27(1):71-80. [MEDLINE: 9565715]
2. Hosseini SH, Espahbodi F, Mirzadeh Goudarzi SM. Citalopram versus psychological training for depression and anxiety symptoms in hemodialysis patients. Iranian Journal of Kidney Diseases 2012;6(6):446-51. [MEDLINE: 23146983]
3. Taraz M, Khatami MR, Dashti-Khavidaki S, Akhonzadeh S, Noorbala AA, Ghaeli P, et al. Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial. International Immunopharmacology 2013;17(3):917-23. [MEDLINE: 24121064]
4. Yazici AE, Erdem P, Erdem A, Yazici K, Acar ST, Basterzi AD, et al. Efficacy and tolerability of escitalopram in depressed patients with end stage renal disease: an open placebo-controlled study [Depresyonu olan son donem bobrek yetmezligi hastalarinda essitalopramin etkinligi ve tolerabilitesi: Bir acik plasebo kontrollu calisma]. Klinik Psikofarmakoloji Bulteni 2012;22(1):23-30. [EMBASE: 2012129390]
5. Paniagua R, Amato D, Mujais S, Vonesh E, Ramos A, Correa-Rotter R, et al. Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. Clinical Journal of The American Society of Nephrology: CJASN 2008;3(2):407-15. [MEDLINE: 18199844]
6. Paniagua R, Amato D, Ramos A, Vonesh EF, Mujais SK, the Mexican Nephrology Collaborative Study Group. Summary results of the Mexican adequacy (ADEMEX) clinical trial on mortality and morbidity in peritoneal dialysis [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):235A. [CENTRAL: CN-00447090]
7. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. Journal of the American Society of Nephrology 2002;13(5):1307-20. [MEDLINE: 11961019]
8. Paniagua R, Amato D, Vonesh E, Guo A, Mujais S. Effects of increased peritoneal clearances on patient quality of life: results from the ADEMEX trial [abstract no: SU-PO933]. Journal of the American Society of Nephrology 2003;14(Nov):741A. [CENTRAL: CN-00550541]
9. Paniagua R, Amato D, Vonesh E, Guo A, Mujais S, Mexican Nephrology Collaborative Study Group. Health-related quality of life predicts outcomes but is not affected by peritoneal clearance: The ADEMEX trial. Kidney international 2005;67(3):1093-104. [MEDLINE: 15698450]
10. Paniagua R, Amato D, Vonesh E, Mujais S. Effects of increasing dialysis prescription on residual renal function: results from the ADEMEX trial. [abstract no: SU-PO931]. Journal of the American Society of Nephrology 2003;14(Nov):740A. [CENTRAL: CN-00550558]
11. Sloand JA, Leypoldt JK, Culleton BF, Gellens ME, Paniagua R, Amato D, et al. Assessing creatinine clearance from modification of diet in renal disease study equations in the ADEMEX cohort: limitations and potential applications. Clinical Journal of The American Society of Nephrology: CJASN 2011;6(3):598-604. [MEDLINE: 21164018]
12. Ancarani E, Biondi B, Bolletta A, Cestra D, De Bella E, Nirchi MA, et al. Major depression complicating hemodialysis in patients with chronic renal failure: A multicenter, double-blind, controlled clinical trial of S- adenosyl-L-methionine versus placebo. Current Therapeutic Research - Clinical & Experimental 1993;54(6):680-6. [EMBASE: 1994039415]
13. Briggs LA, Kirchhoff KT, Hammes BJ, Song MK, Colvin ER. Patient-centered advance care planning in special patient populations: a pilot study. Journal of Professional Nursing 2004;20(1):47-58. [MEDLINE: 15011193]
14. Jain N, Trivedi MH, Rush AJ, Carmody T, Kurian B, Toto RD, et al. Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). Contemporary Clinical Trials 2013;34(1):136-44. [MEDLINE: 23085503]
15. Chang ST, Chen CL, Chen CC, Hung KC. Clinical events occurrence and the changes of quality of life in chronic haemodialysis patients with dry weight determined by echocardiographic method. International Journal of Clinical Practice 2004;58(12):1101-7. [MEDLINE: 15646404]
16. Chang ST, Chen CL, Chen CC, Lin FC, Wu D. Enhancement of quality of life with adjustment of dry weight by echocardiographic measurement of inferior vena cava diameter in patients undergoing chronic hemodialysis. Nephron Clinical Practice 2004;97(3):C90-7. [MEDLINE: 15292685]
17. Cho YC, Tsay SL. The effect of acupressure with massage on fatigue and depression in patients with end-stage renal disease. Journal of Nursing Research 2004;12(1):51-9. [MEDLINE: 15136963]
18. Ciarambino T, Ferrara N, Castellino P, Paolisso G, Coppola L, Giordano M. Effects of six days a week low protein dietary intervention on depressive symptoms in elderly diabetic subjects [Effetti della dieta ipoproteica 6 giorni la settimana sui sintomi depressivi in anziani diabetici tipo 2]. Giornale di Gerontologia 2012;60(1):8-13. [EMBASE: 2012317209]
19. De Felice SL, Lyons MD, Gaffar MC, Sheridan MJ. U.S. - Italy L-carnitine hemodialysis utilization survey. Dialysis & Transplantation 1996;25(6):368-73. [EMBASE: 1996178046]
20. Deniston OL, Luscombe FA, Buesching DP, Richner RE, Spinowitz BS. Effect of long-term epoetin beta therapy on the quality of life of hemodialysis patients. ASAIO Transactions 1990;36(3):157-60. [MEDLINE: 2123632]
21. dos Reis Santos I, Danaga AR, de Carvalho Aguiar I, Oliveira EF, Dias IS, Urbano JJ, et al. Cardiovascular risk and mortality in end-stage renal disease patients undergoing dialysis: sleep study, pulmonary function, respiratory mechanics, upper airway collapsibility, autonomic nervous activity, depression, anxiety, stress and quality of life: a prospective, double blind, randomized controlled clinical trial. BMC Nephrology 2013;14(1):215. [MEDLINE: 24103561]
22. Agar BU, Culleton BF, Fluck R, Leypoldt JK. Potassium kinetics during hemodialysis. Hemodialysis International 2015;19(1):23-32. [MEDLINE: 25091596]
23. Allen K, Dwyer JT, Frydrych A, Leung J, Paranandi L, Poole D, et al. Predictors of functional ability at baseline in the hemodialysis (HEMO) study [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):152-3A. [CENTRAL: CN-00520312]
24. Allon M, Depner TA, HEMO Study Group. Effect of hemodialysis dose and membrane on infectious outcomes: results from the HEMO study [abstract no: SA-P0766]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):421A. [CENTRAL: CN-00444149]
25. Allon M, Ornt DB, Schwab SJ, Delmez J, Kusek JA, Martin AA, et al. Factors determining the prevalence of A-V fistulas (AVF) in hemodialysis (HD) patients in the HEMO study [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):200A. [CENTRAL: CN-00550466]
26. Allon M, Radeva M, Bailey J, Beddhu S, Butterly D, Coyne DW, et al. Association of serum albumin and disease category with severity of infection: data from the HEMO study [abstract no: SU-PO840]. Journal of the American Society of Nephrology 2003;14(Nov):720A. [CENTRAL: CN-00550473]
27. Argyropoulos C, Larive B, Miskulin D, Greene T, Beddhu S, Rocco M, et al. Predictors of mortality and hospitalization among elderly hemodialysis patients over a three year period [abstract no: SU-PO595]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):715A. [CENTRAL: CN-00747279]
28. Argyropoulos C, Roumelioti ME, Cheung A, Kellum JA, Weissfeld L, Unruh M. Dialyzer reuse and patient outcomes in the HEMO Study [abstract no: M676]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009.
29. Athienites NV, Meyer KB, Martin A, Gassman JJ, Levey AS, Hemodialysis (HEMO) Study. Baseline health status and comorbidity in the HEMO pilot study [abstract]. Journal of the American Society of Nephrology 1995;6(3):518. [CENTRAL: CN-00483061]
30. Balakrishnan VS, Guo D, Perianayagam MC, Jaber BL, Pereira BJ, Rao M, et al. Plasma IL-6 predicts clinical outcomes in prevalent hemodialysis patients [abstract]. Journal of the American Society of Nephrology 2003;14(Nov):3A. [CENTRAL: CN-00550425]
31. Beddhu S, Baird B, Ma X, Cheung AK, Greene T. Serum alkaline phosphatase and mortality in hemodialysis patients. Clinical Nephrology 2010;74(2):91-6. [MEDLINE: 20630128]
32. Beddhu S, Kaysen GA, Yan G, Sarnak M, Agodoa L, Ornt D, et al. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. American Journal of Kidney Diseases 2002;40(4):721-7. [MEDLINE: 12324906]
33. Beddhu S, Yan G, Agodoa L, Beck G, Milford E, Miskulin D, et al. The impact of race and comorbidity on kidney transplantation (KTx) in the HEMO study [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):877A. [CENTRAL: CN-00520319]
34. Benz RL, Pressman MR, Brown J. Does membrane flux (F) or dialysis eKT/V dose (K) affect ESRD-related sleep disorders in hemodialysis (HD) patients (Pts)? An ancillary study of the HEMO trial [abstract no: F-FC095]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):20A. [CENTRAL: CN-00444399]
35. Briggs JP. Evidence-based medicine in the dialysis unit: a few lessons from the USRDS and the NCDS and HEMO trials. Seminars in Dialysis 2004;17(2):136-41. [MEDLINE: 15043616]
36. Burrowes JD, Cockram DB, Dwyer JT, Larive B, Paranandi L, Bergen C, et al. Cross-sectional relationship between dietary protein and energy intake, nutritional status, functional status, and comorbidity in older versus younger hemodialysis patients. Journal of Renal Nutrition 2002;12(2):87-95. [MEDLINE: 11953921]
37. Burrowes JD, Larive B, Chertow GM, Cockram DB, Dwyer JT, Greene T, et al. Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. Nephrology Dialysis Transplantation 2005;20(12):2765-74. [MEDLINE: 16204298]
38. Burrowes JD, Larive B, Cockram DB, Dwyer J, Kusek JW, McLeroy S, et al. Effects of dietary intake, appetite, and eating habits on dialysis and non-dialysis treatment days in hemodialysis patients: cross-sectional results from the HEMO study. Journal of Renal Nutrition 2003;13(3):191-8. [MEDLINE: 12874743]
39. Burrowes JD, Russell GB, Unruh M, Rocco MV. Is nutritional status associated with self-reported sleep quality in the HEMO study cohort?. Journal of Renal Nutrition 2012;22(5):461-71. [MEDLINE: 22056151]
40. Chang TI, Flythe JE, Brunelli SM, Muntner P, Greene T, Cheung AK, et al. Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis. Journal of Human Hypertension 2014;28(1):18-24. [MEDLINE: 23803593]
41. Chang TI, Friedman GD, Cheung AK, Greene T, Desai M, Chertow GM. Systolic blood pressure and mortality in prevalent haemodialysis patients in the HEMO study. Journal of Human Hypertension 2011;25(2):98-105. [MEDLINE: 20410919]
42. Chang TI, Paik J, Greene T, Desai M, Bech F, Cheung AK, et al. Intradialytic hypotension and vascular access thrombosis. Journal of the American Society of Nephrology 2011;22(8):1526-33. [MEDLINE: 21803971]
43. Chang TI, Paik J, Greene T, Miskulin DC, Chertow GM. Updated comorbidity assessments and outcomes in prevalent hemodialysis patients. Hemodialysis International 2010;14(4):478-85. [MEDLINE: 20955281]
44. Chang TI, Shilane D, Brunelli SM, Cheung AK, Chertow GM, Winkelmayer WC. Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. American Heart Journal 2011;162(2):324-30. [MEDLINE: 21835294]
45. Chelamcharla M, Yan G, Rocco M, Schulman G, Teehan B, Toto R, et al. Effect of hemodialysis dose and flux on lipoproteins (LP) in the HEMO study [abstract no: W-PO40022]. Nephrology 2005;10(Suppl 1):A285. [CENTRAL: CN-00782977]
46. Cheung AK, Agodoa L, Daugirdas JT, Greene T, Levey AS, Milford E, Ornt DB, et al. Predictive value of blood pressure (BP) for mortality in chronic hemodialysis (HD) patients changes with duration of follow-up [abstract]. Journal of the American Society of Nephrology 2003;14(Nov):2A. [CENTRAL: CN-00583167]
47. Cheung AK, Agodoa LY, Daugirdas JT, Depner TA, Gotch FA, Greene T, et al. Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. The Hemodialysis (HEMO) Study Group. Journal of the American Society of Nephrology 1999;10(1):117-27. [MEDLINE: 9890317]
48. Cheung AK, Greene T, Leypoldt JK, Yan G, Allon M, Delmez J, et al. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(1):69-77. [MEDLINE: 18057309]
49. Cheung AK, Levey AS, HEMO Study Group. Effect of dialysis dose and membrane on cardiac outcomes: results from the HEMO Study [abstract]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):421A. [CENTRAL: CN-00444794]
50. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. Journal of the American Society of Nephrology 2003;14(12):3251-63. [MEDLINE: 14638924]
51. Cheung AK, Levin NW, HEMO Study Group. Effect of high flux (HF) hemodialysis (HD) membranes on clinical outcomes: results from the HEMO study [abstract]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):432A. [CENTRAL: CN-00444795]
52. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. Journal of the American Society of Nephrology 2006;17(2):546-55. [MEDLINE: 16382021]
53. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney International 2004;65(6):2380-9. [MEDLINE: 15149351]
54. Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. Journal of the American Society of Nephrology 2016;27(1):227-37. [MEDLINE: 25971439]
55. Chumlea WC, Bergen C, Dwyer J, McGhee HA, McLeroy S, Paranandi L. Anthropometric data for hemodialysis patients: an interim report from the HEMO study [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):189A. [CENTRAL: CN-00444834]
56. Cockram D, Bergen C, Burrowes J, Larive B, Leung J, Poole D, et al. Oral enteral supplement use during baseline in the HEMO trial [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):353A. [CENTRAL: CN-00444865]
57. Daugirdas J, Depner T, Gotch F, Greene T, Levin N, Schulman G, et al. Predictors of urea rebound [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):296A. [CENTRAL: CN-00444990]
58. Daugirdas J, Greene T, Levin N, Maroni B, Schulman G, Star R. Modeled/anthropometric volume ratios: effect of age, race, and different formulas [abstract no: A1305]. Journal of the American Society of Nephrology 1996;7(9):1510. [CENTRAL: CN-00583704]
59. Daugirdas J, Levin N, Bailey J, Beck G, Cheung A, Greene T, et al. Occurrence of intradialytic hypotension (IH) as a risk factor for mortality in the HEMO study [abstract no: SU-PO803]. Journal of the American Society of Nephrology 2003;14(Nov):711A. [CENTRAL: CN-00550388]
60. Daugirdas JT, Depner TA, Gotch FA, Greene T, Keshaviah P, Levin NW, et al. Comparison of methods to predict equilibrated Kt/V in the HEMO Pilot Study. Kidney International 1997;52(5):1395-405. [MEDLINE: 9350665]
61. Daugirdas JT, Depner TA, HEMO Study Group. Association of achieved eKt/V with mortality: an example of dose targeting bias [abstract]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):613-4A. [CENTRAL: CN-00444992]
62. Daugirdas JT, Greene T, Chertow GM, Depner TA. Can rescaling dose of dialysis to body surface area in the HEMO study explain the different responses to dose in women versus men?. Clinical Journal of the American Society of Nephrology: CJASN 2010;5(9):1628-36. [MEDLINE: 20595687]
63. Daugirdas JT, Greene T, Cheung AK, Beck GJ, Levin NW, Kusek JW, et al. Effect of membrane flux intervention in HEMO study patients when grouped by months on dialysis at randomization, serum albumin, diabetes, and b2-M clearance [abstract no: SA-PO2611]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):698A. [CENTRAL: CN-00782996]
64. Daugirdas JT, Greene T, Depner TA, Levin NW, Chertow GM. Modeled urea distribution volume and mortality in the HEMO Study. Clinical Journal of the American Society of Nephrology: CJASN 2011;6(5):1129-38. [MEDLINE: 21511841]
65. Daugirdas JT, Greene T, Depner TA, Leypoldt J, Gotch F, Schulman G, et al. Factors that affect postdialysis rebound in serum urea concentration, including the rate of dialysis: results from the HEMO Study. Journal of the American Society of Nephrology 2004;15(1):194-203. [MEDLINE: 14694173]
66. Delmez J, Beck G, Beddhu S, Levey A, Sarnak M, Yan G, et al. Effect of high flux hemodialysis (HD) on cerebrovascular (CBV) deaths: results from the HEMO study [abstract no: SU-PO345]. Journal of the American Society of Nephrology 2004;15(Oct):609A. [CENTRAL: CN-00550767]
67. Delmez JA, Yan G, Bailey J, Beck GJ, Beddhu S, Cheung AK, et al. Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. American Journal of Kidney Diseases 2006;47(1):131-8. [MEDLINE: 16377394]
68. Depner T, Daugirdas J, Greene T, Allon M, Beck G, Chumlea C, et al. Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney International 2004;65(4):1386-94. [MEDLINE: 15086479]
69. Depner TA, Daugirdas JT, HEMO Study Group. Does gender influence the effect of dialysis dose on mortality? Results of the HEMO study [abstract no: SA-PO770]. Journal of the American Society of Nephrology 2002;13:422A. [CENTRAL: CN-00445075]
70. Depner TA, Gotch F, Daugirdas JT, Greene T, Kaufman AM, Hemodialysis (HEMO) Study. Monitoring dialysis therapy using estimates of amount of urea removed and mean urea volume [abstract]. Journal of the American Society of Nephrology 1995;6(3):597. [CENTRAL: CN-00483727]
71. Depner TA, Gotch FA, Port FK, Wolfe RA, Lindsay RM, Blake PG, et al. How will the results of the HEMO study impact dialysis practice?. Seminars in Dialysis 2003;16(1):8-21. [MEDLINE: 12535292]
72. Depner TA, Greene T, Gotch FA, Daugirdas JT, Keshaviah PR, Star RA, et al. Imprecision of the hemodialysis dose when measured directly from urea removal. Hemodialysis Study Group. Kidney International 1999;55(2):635-47. [MEDLINE: 9987088]
73. Dwyer JT, Bergen C, Daugirdas J, Larive B, Leung J, Rocco M, et al. Baseline associations between estimated resting metabolic rate and energy intake in the hemodialysis (HEMO) study [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):355A. [CENTRAL: CN-00445182]
74. Dwyer JT, Chumlea WC, Frydrych A, Kusek J, Leung J, Paranandi L, et al. Better nutritional status and lower comorbidity associated with quality of life at baseline in the HEMO Study [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):206A. [CENTRAL: CN-00445183]
75. Dwyer JT, Cunniff PJ, Maroni BJ, Kopple JD, Burrowes JD, Powers SN, et al. The hemodialysis pilot study: nutrition program and participant characteristics at baseline. The HEMO Study Group.[Erratum appears in J Ren Nutr 1998 Oct;8(4):230]. Journal of Renal Nutrition 1998;8(1):11-20. [MEDLINE: 9724825]
76. Dwyer JT, Kopple JD, Maroni BJ, Burrowes JD, Powers SN, Cockram DB, et al. Dietary intake and nutritional status in the HEMO pilot study population [abstract]. Journal of the American Society of Nephrology 1995;6(3):576. [CENTRAL: CN-00483815]
77. Dwyer JT, Larive B, Leung J, Rocco M, Burrowes JD, Chumlea WC, et al. Nutritional status affects quality of life in Hemodialysis (HEMO) Study patients at baseline. Journal of Renal Nutrition 2002;12(4):213-23. [MEDLINE: 12382213]
78. Dwyer JT, Larive B, Leung J, Rocco MV, Greene T, Burrowes J, et al. Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study?. Kidney International 2005;68(4):1766-76. [MEDLINE: 16164653]
79. Dwyer JT, Leung J, Larive B, Rocco MV, Greene T, Burrowes J, et al. Are common nutritional risk factors among the strongest mortality predictors when also considering case-mix? Results from the hemodialysis (HEMO) study [abstract no: SA-PO368]. Journal of the American Society of Nephrology 2004;15(Oct):382A. [CENTRAL: CN-00550516]
80. Eknoyan G, Agodoa L, Beck G, Daugirdas J, Greene T, Kusek J, et al. Adequacy of delivered dialysis doses in the HEMO study: an interim report [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):282A. [CENTRAL: CN-00445206]
81. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. New England Journal of Medicine 2002;347(25):2010-9. [MEDLINE: 12490682]
82. Eknoyan G, Beck GJ, Kusek JW, Levey AS, Levin NW, et al. Design, characterization of prevalent patients, and progress of the hemodialysis (HEMO) study [abstract]. Journal of the American Society of Nephrology 1995;6(3):598. [CENTRAL: CN-00484324]
83. Eknoyan G, Greene T, HEMO Study Group. Primary results from the HEMO study [abstract no: SA-PO767]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):421A. [CENTRAL: CN-00445207]
84. Eknoyan G, HEMO Study Group. The US mortality and morbidity of haemodialysis (HEMO) study. Design and results of the pilot phase [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong. 1995:19. [CENTRAL: CN-00460693]
85. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney International 2011;79(2):250-7. [MEDLINE: 20927040]
86. Greene T, Beck GJ, Gassman JJ, Gotch FA, Kusek JW, Levey AS, et al. Design and statistical issues of the hemodialysis (HEMO) study. Controlled Clinical Trials 2000;21(5):502-25. [MEDLINE: 11018567]
87. Greene T, Daugirdas J, Depner T, Allon M, Beck G, Chumlea C, et al. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias". Journal of the American Society of Nephrology 2005;16(11):3371-80. [MEDLINE: 16192421]
88. Greene T, Kusek JK, Levin NW. Progress and adequacy of delivered dialysis doses in the hemodialysis (HEMO) study: interim results [abstract]. 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy. 1998:253.
89. HEMO Study Group. Comparison of methods to predict the equilibrated kt/v (eKTV) in the HEMO study [abstract]. Journal of the American Society of Nephrology 1995;6(3):596. [CENTRAL: CN-00484323]
90. Hemo Study Group, Eknoyan G, Beck GJ, Kusek JW, Levin NW. Progress of the hemodialysis (HEMO) study [abstract]. Nephrology 1997;3(Suppl 1):S419. [CENTRAL: CN-00460926]
91. Kang EW, Pike F, Ramer S, Abdel-Kader K, Myaskovsky L, Dew MA, et al. The association of mental health over time with cardiac outcomes in HEMO study patients. Clinical Journal of the American Society of Nephrology: CJASN 2012;7(6):957-64. [MEDLINE: 22490873]
92. Kaysen GA, Greene T, Daugirdas JT, Kimmel PL, Schulman GW, Toto RD, et al. Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients. American Journal of Kidney Diseases 2003;42(6):1200-11. [MEDLINE: 14655192]
93. Leung J, Dwyer J, Cockram D, Rocco M, Larive B, Chumlea C, et al. Association of nutritional parameters with mortality depends on length of follow-up [abstract no: SA-PO928]. Journal of the American Society of Nephrology 2003;14(Nov):503A. [CENTRAL: CN-00550731]
94. Leung J, Larive B, Dwyer J, Hibberd P, Jacques P, Rand W, et al. Folic acid supplementation and cardiac and stroke mortality among hemodialysis patients. Journal of Renal Nutrition 2010;20(5):293-302. [MEDLINE: 20303789]
95. Levey A, Athienites NV, Gassman JJ, Martin AA, Ornt DB, Kusek JW, et al. Comorbidity assessment in the HEMO study: an interim report [abstract no: A0933]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):201A. [CENTRAL: CN-00446339]
96. Leypoldt JK, Cheung AK, Agodoa LY, Daugirdas JT, Greene T, Keshaviah PR, et al. Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. The Hemodialysis (HEMO) Study. Kidney International 1997;51(6):2013-7. [MEDLINE: 9186896]
97. Leypoldt JK, Cheung AK, Clark WR, Daugirdas JT, Gotch FA, Greene T, et al. Characterization of low and high flux dialyzers with reuse in the HEMO study: interim report [abstract no: A1345]. Journal of the American Society of Nephrology 1996;7(9):1518. [CENTRAL: CN-00583522]
98. Liang KV, Pike F, Argyropoulos C, Weissfeld L, Teuteberg J, Dew MA, et al. Heart failure severity scoring system and medical- and health-related quality-of-life outcomes: The HEMO study. American Journal of Kidney Diseases 2011;58(1):84-92. [MEDLINE: 21549465]
99. Liu T, Liang KV, Rosenbaum A, Stephenson R, Pike F, Weissfeld L, et al. Peripheral vascular disease severity impacts health outcomes and health-related quality of life in maintenance hemodialysis patients in the HEMO Study. Nephrology Dialysis Transplantation 2012;27(7):2929-36. [MEDLINE: 22273665]
100. Locatelli F. Effect of dialysis dose and membrane flux in maintenance hemodialysis. New England Journal of Medicine 2003;348(15):1491-4. [MEDLINE: 12691051]
101. Lynch KE, Lynch R, Curhan GC, Brunelli SM. Altered taste perception and nutritional status among hemodialysis patients. Journal of Renal Nutrition 2013;23(4):288-95. [MEDLINE: 23046735]
102. Lynch KE, Lynch R, Curhan GC, Brunelli SM. Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN 2011;6(3):620-9. [MEDLINE: 21148246]
103. Maroni B, Burkart J, Burrowes J, Cockram D, Drabik M, Dwyer J, et al. Baseline nutritional characteristics of the HEMO study participants: interim report [abstract no: A1041]. Journal of the American Society of Nephrology 1996;7(9):1456. [CENTRAL: CN-00583818]
104. Maroni B, Burkhart J, Burrowes J, Dwyer J, Henry R, Kusek J, et al. Relationship between dialysis dose, membrane flux and indices of nutritional status at baseline in the HEMO study: an interm report [abstract no: A1322]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):288A. [CENTRAL: CN-00446608]
105. Mc Causland FR, Brunelli SM, Waikar SS. Dialysis dose and intradialytic hypotension: results from the HEMO study. American Journal of Nephrology 2013;38(5):388-96. [MEDLINE: 24192428]
106. Mc Causland FR, Waikar SS, Brunelli SM. Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients. Kidney International 2012;82(2):204-11. [MEDLINE: 22418981]
107. Meyer K, Benz R, HEMO Study Group. Quality of life (QOL) outcomes in the HEMO study [abstract no: SA-P0796]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):421A. [CENTRAL: CN-00446759]
108. Meyer KB, Paranandi L, Hays R, Benz R, Athienites N, Kusek J, et al. Clinical correlates of baseline quality of life in the HEMO study: an interim report [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):204A. [CENTRAL: CN-00446757]
109. Meyer KB, Paranandi L, Hays R, Benz R, Athienites N, Kusek J, et al. Quality of life in the HEMO study: an interim report [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):204A. [CENTRAL: CN-00446758]
110. Miskulin DC, Athienites NV, Yan G, Martin AA, Ornt DB, Kusek JW, et al. Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial. Kidney International 2001;60(4):1498-510. [MEDLINE: 11576365]
111. Ng Y, Unruh ML, Kusek JW, Meyer KB, Yan G, Rocco MV, et al. Hemodialysis timing, survival and cardiovascular outcomes in the HEMO study [abstract no: SU-PO439]. Journal of the American Society of Nephrology 2004;15(Oct):630A. [CENTRAL: CN-00550583]
112. Ng YH, Meyer KB, Kusek JW, Yan G, Rocco MV, Kimmel PL, et al. Hemodialysis timing, survival, and cardiovascular outcomes in the Hemodialysis (HEMO) study. American Journal of Kidney Diseases 2006;47(4):614-24. [MEDLINE: 16564939]
113. Rao M, Guo D, Perianayagam MC, Jaber BL, Pereira BJ, Balakrishnan VS, et al. Comparative predictive power of CRP and IL-6 for all-cause and cardiovascular mortality in end-stage renal disease [abstract no: F-PO452]. Journal of the American Society of Nephrology 2004;15(Oct):166A. [CENTRAL: CN-00583200]
114. Rao M, Guo D, Perianayagam MC, Jaber BL, Pereira BJ, Balakrishnan VS, et al. Cytokine gene polymorphisms modulate acute phase response among hemodialysis patients [abstract no: F-PO460]. Journal of the American Society of Nephrology 2004;15(Oct):167A. [CENTRAL: CN-00583202]
115. Rao M, Li L, Bertrand LJ, Pereira BJ, Balakrishnan VS, HEMO Study Group. Plasma adiponectin and clinical outcomes among hemodialysis patients [abstract no: 133]. American Journal of Kidney Diseases 2006;47(4):A52.
116. Rao M, Li L, Menon V, Balakrishnan VS. Plasma adiponectin and clinical outcomes among hemodialysis patients [abstract no: F-PO619]. Journal of the American Society of Nephrology 2006;17(Abstracts):468A. [CENTRAL: CN-00583203]
117. Rao M, Menon V, Balakrishnan VS. Determinants of adiponectin levels in hemodialysis patients [abstract no: F-PO618]. Journal of the American Society of Nephrology 2006;17(Abstracts):468A. [CENTRAL: CN-00602005]
118. Rocco M, Benz R, Burkart J, Cheung A, Heyka R, Irving S, et al. Baseline blood pressure in HEMO study participants: an interim report [abstract no: A1153]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):250-1A. [CENTRAL: CN-00447425]
119. Rocco M, Dwyer J, HEMO Study Group. Effect of dose and flux interventions on nutritional parameters: results from the hemodialysis study [abstract no: SA-P0768]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):421A. [CENTRAL: CN-00447426]
120. Rocco M, Miskulin D, Unruh M, Yan G, Athienites N, Kusek J, et al. Modification of the ICED to improve its predictive ability for mortality in chronic hemodialysis patients: results from the hemodialysis (HEMO) study [abstract no: SA-PO380]. Journal of the American Society of Nephrology 2004;15(Oct):385A. [CENTRAL: CN-00550559]
121. Rocco MV, Dwyer JT, Larive B, Greene T, Cockram DB, Chumlea WC, et al. The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: results of the HEMO Study. Kidney International 2004;65(6):2321-34. [MEDLINE: 15149346]
122. Rocco MV, Paranandi L, Burrowes JD, Cockram DB, Dwyer JT, Kusek JW, et al. Nutritional status in the HEMO Study cohort at baseline. American Journal of Kidney Diseases 2002;39(2):245-56. [MEDLINE: 11840364]
123. Rocco MV, Yan G, Gassman J, Lewis J, Ornt D, Weiss B, et al. A comparison of causes of death in the HEMO study with the HCFA death notification form [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):254A. [CENTRAL: CN-00550561]
124. Rocco MV, Yan G, Gassman J, Lewis JB, Ornt D, Weiss B, et al. Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration. American Journal of Kidney Diseases 2002;39(1):146-53. [MEDLINE: 11774113]
125. Rocco MV, Yan G, Heyka RJ, Benz R, Cheung AK, HEMO Study Group. Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. American Journal of Nephrology 2001;21(4):280-8. [MEDLINE: 11509799]
126. Sattar A, Argyropoulos C, Weissfeld L, Younas N, Fried L, Kellum JA, et al. All-cause and cause-specific mortality associated with diabetes in prevalent hemodialysis patients. BMC Nephrology 2012;13:130. [MEDLINE: 23025844]
127. Su CT, Yabes J, Pike F, Weiner DE, Beddhu S, Burrowes JD, et al. Changes in anthropometry and mortality in maintenance hemodialysis patients in the HEMO Study. American Journal of Kidney Diseases 2013;62(6):1141-50. [MEDLINE: 23859719]
128. Tangri N, Shastri S, Tighiouart H, Beck GJ, Cheung AK, Eknoyan G, et al. beta-Blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study. American Journal of Kidney Diseases 2011;58(6):939-45. [MEDLINE: 21872979]
129. Unruh M, Benz R, Greene T, Yan G, Beddhu S, DeVita M, et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney international 2004;66(1):355-66. [MEDLINE: 15200444]
130. Unruh M, Miskulin D, Yan G, Hays RD, Benz R, Kusek JW, et al. Racial differences in health-related quality of life among hemodialysis patients. Kidney International 2004;65(4):1482-91. [MEDLINE: 15086492]
131. Unruh M, Yan G, Radeva M, Hays RD, Benz R, Athienites NV, et al. Bias in assessment of health-related quality of life in a hemodialysis population: a comparison of self-administered and interviewer-administered surveys in the HEMO study. Journal of the American Society of Nephrology 2003;14(8):2132-41. [MEDLINE: 12874468]
132. Unruh ML, Newman AB, Larive B, Amanda DM, Miskulin DC, Greene T, et al. The influence of age on changes in health-related quality of life over three years in a cohort undergoing hemodialysis. Journal of the American Geriatrics Society 2008;56(9):1608-17. [MEDLINE: 18721224]
133. Uribarri J, Levin N, Delmez J, Depner T, Ornt D, Owen W, et al. Association of acidosis and nutritional parameters in hemodialysis (HD) patients [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):108A. [CENTRAL: CN-00448101]
134. Uribarri J, Levin NW, Delmez J, Depner TA, Ornt D, Owen W, et al. Association of acidosis and nutritional parameters in hemodialysis patients. American Journal of Kidney Diseases 1999;34(3):493-9. [MEDLINE: 10469860]
135. Vlagopoulos P, Sarnak M, Yan G, Herzog C, Ornt D, Kusek J, et al. Risk factors for sudden death (SD) in chronic hemodialysis [abstract no: SU-PO346]. Journal of the American Society of Nephrology 2004;15(Oct):609A. [CENTRAL: CN-00550660]
136. Waikar SS, Curhan GC, Brunelli SM. Mortality associated with low serum sodium concentration in maintenance hemodialysis. American Journal of Medicine 2011; Vol. 124, issue 1:77-84. [MEDLINE: 21187188]
137. Wald R, Sarnak MJ, Tighiouart H, Cheung AK, Levey AS, Eknoyan G, et al. Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. American Journal of Kidney Diseases 2008;52(3):531-40. [MEDLINE: 18657891]
138. Kennedy SH, Craven JL, Rodin GM, Roin GM. Major depression in renal dialysis patients: an open trial of antidepressant therapy.[Erratum appears in J Clin Psychiatry 1989 Apr;50(4):148 Note: Roin GM [corrected to Rodin GM]]. Journal of Clinical Psychiatry 1989;50(2):60-3. [MEDLINE: 2644243]
139. Koo JR, Yoon JY, Joo MH, Lee HS, Oh JE, Kim SG, et al. Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. American Journal of the Medical Sciences 2005;329(1):1-5. [MEDLINE: 15654172]
140. Kurella M, Yaffe K, Shlipak MG, Wenger NK, Chertow GM. Chronic kidney disease and cognitive impairment in menopausal women. American Journal of Kidney Diseases 2005;45(1):66-76. [MEDLINE: 15696445]
141. Levy NB, Blumenfield M, Beasley CM Jr, Dubey AK, Solomon RJ, Todd R, et al. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. General Hospital Psychiatry 1996;18(1):8-13. [MEDLINE: 8666216]
142. Lieh Yeh T, Liang Huang C, Kuang Yang Y, Dar Lee Y, Cheng Chen C, See Chen P. The adjustment to illness in patients with generalized anxiety disorder is poorer than that in patients with end-stage renal disease. Journal of Psychosomatic Research 2004;57(2):165-70. [MEDLINE: 15465071]
143. Miller DK, Chibnall JT, Videen SD, Duckro PN. Supportive-affective group experience for persons with life-threatening illness: reducing spiritual, psychological, and death-related distress in dying patients. Journal of Palliative Medicine 2005;8(2):333-43. [MEDLINE: 15890044]
144. Moug SJ, Grant S, Creed G, Boulton Jones M. Exercise during haemodialysis: West of Scotland pilot study. Scottish Medical Journal 2004;49(1):14-7. [MEDLINE: 15012046]
145. Pearlman C, Carson W, Metz A. Hemodialysis, chronic renal failure, and ECT. Convulsive Therapy 1988;4(4):332-3.
146. Seabolt JL, De Leon OA. Response to nefazodone in a depressed patient with end-stage renal disease. General Hospital Psychiatry 2001;23(1):45-6. [MEDLINE: 11291641]
147. Sharp J, Wild MR, Gumley AI, Deighan CJ. A cognitive behavioral group approach to enhance adherence to hemodialysis fluid restrictions: a randomized controlled trial. American Journal of Kidney Diseases 2005;45(6):1046-57. [MEDLINE: 15957134]
148. Green JA, Mor MK, Shields AM, Sevick MA, Arnold RM, Palevsky PM, et al. Associations of health literacy with dialysis adherence and health resource utilization in patients receiving maintenance hemodialysis. American Journal of Kidney Diseases 2013;62(1):73-80. [MEDLINE: 23352380]
149. Green JA, Mor MK, Shields AM, Sevick MA, Palevsky PM, Fine MJ, et al. Prevalence and demographic and clinical associations of health literacy in patients on maintenance hemodialysis. Clinical Journal of the American Society of Nephrology 2011;6(6):1354-60. [MEDLINE: 21551025]
150. Green JA, Mor MK, Shields AM, Sevik MA, Palevsky PM, Fine MJ, et al. Renal provider perceptions and practice patterns regarding the management of pain, sexual dysfunction, and depression in hemodialysis patients. Journal of Palliative Medicine 2012;15(2):163-7. [MEDLINE: 22339326]
151. Mor MK, Sevick MA, Shields AM, Green JA, Palevsky PM, Arnold RM, et al. Sexual function, activity, and satisfaction among women receiving maintenance hemodialysis. Clinical Journal of the American Society of Nephrology 2014;9(1):128-34. [MEDLINE: 24357510]
152. Weisbord SD, Mor MK, Green JA, Sevick MA, Shields AM, Zhao X, et al. Comparison of symptom management strategies for pain, erectile dysfunction, and depression in patients receiving chronic hemodialysis: a cluster randomized effectiveness trial. Clinical Journal of the American Society of Nephrology: CJASN 2013;8(1):90-9. [MEDLINE: 23024159]
153. Weisbord SD, Mor MK, Sevick MA, Shields AM, Rollman BL, Palevsky PM, et al. Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN 2014;9(9):1594-602. [MEDLINE: 25081360]
154. Weisbord SD, Shields AM, Mor MK, Sevick MA, Homer M, Peternel J, et al. Methodology of a randomized clinical trial of symptom management strategies in patients receiving chronic hemodialysis: the SMILE study. Contemporary Clinical Trials 2010;31(5):491-7. [MEDLINE: 20601163]
155. Atalay H, Solak Y, Biyik Z, Gaipov A, Guney F, Turk S. Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clinical Drug Investigation 2013;33(6):401-8. [MEDLINE: 23572323]
156. Biyik Z, Solak Y, Atalay H, Gaipov A, Guney F, Turk S. Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. International Urology & Nephrology 2013;45(3):831-7. [MEDLINE: 22644743]
157. Solak Y, Biyik Z, Atalay H, Gaipov A, Guney F, Turk S, et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology 2012;17(8):710-7. [MEDLINE: 22909343]
158. Tsay SL. Acupressure and fatigue in patients with end-stage renal disease-a randomized controlled trial. International Journal of Nursing Studies 2004;41(1):99-106. [MEDLINE: 14670399]
159. Tsay SL, Cho YC, Chen ML. Acupressure and Transcutaneous Electrical Acupoint Stimulation in improving fatigue, sleep quality and depression in hemodialysis patients. American Journal of Chinese Medicine 2004;32(3):407-16. [MEDLINE: 15344424]
160. Tsay SL, Hung LO. Empowerment of patients with end-stage renal disease--a randomized controlled trial. International Journal of Nursing Studies 2004;41(1):59-65. [MEDLINE: 14670395]
161. Tsay SL, Lee YC, Lee YC. Effects of an adaptation training programme for patients with end-stage renal disease. Journal of Advanced Nursing 2005;50(1):39-46. [MEDLINE: 15788064]
162. Solak Y, Atalay H, Kan S, Kaynar M, Bodur S, Yeksan M, et al. Effects of sildenafil and vardenafil treatments on sleep quality and depression in hemodialysis patients with erectile dysfunction. International Journal of Impotence Research 2011;23(1):27-31. [MEDLINE: 21209618]
163. Turk S, Solak Y, Kan S, Atalay H, Kilinc M, Agca E, et al. Effects of sildenafil and vardenafil on erectile dysfunction and health-related quality of life in haemodialysis patients: a prospective randomized crossover study. Nephrology Dialysis Transplantation 2010;25(11):3729-33. [MEDLINE: 20466680]
164. van Vilsteren MC, de Greef MH, Huisman RM. The effects of a low-to-moderate intensity pre-conditioning exercise programme linked with exercise counselling for sedentary haemodialysis patients in The Netherlands: results of a randomized clinical trial. Nephrology Dialysis Transplantation 2005;20(1):141-6. [MEDLINE: 15522901]
165. Wuerth D, Finkelstein SH, Ciarcia J, Peterson R, Kliger AS, Finkelstein FO. Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. American Journal of Kidney Diseases 2001;37(5):1011-7. [MEDLINE: 11325684]
166. Zetin M, Stone RA. Effects of zinc in chronic hemodialysis. Clinical Nephrology 1980;13(1):20-5. [MEDLINE: 6988119]
167. Zetin M, Frost NR, Brumfield D, Stone RA. Amitriptyline stimulates weight gain in hemodialysis patients. Clinical Nephrology 1982;18(2):79-82. [MEDLINE: 6754192]
168. Dashti-Khavidaki S, Gharekhani A, Khatami MR, Miri ES, Khalili H, Razeghi E, et al. Effects of omega-3 fatty acids on depression and quality of life in maintenance hemodialysis patients. American Journal of Therapeutics 2014;21(4):275-87. [MEDLINE: 24987942]
169. Gharekhani A, Khatami MR, Dashti-Khavidaki S, Razeghi E, Abdollahi A, Hashemi-Nazari SS, et al. Effects of oral supplementation with omega-3 fatty acids on nutritional state and inflammatory markers in maintenance hemodialysis patients. Journal of Renal Nutrition 2014;24(3):177-85. [MEDLINE: 24613294]
170. Gharekhani A, Khatami MR, Dashti-Khavidaki S, Razeghi E, Noorbala AA, Hashemi-Nazari SS, et al. The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial. European Journal of Clinical Pharmacology 2014;70(6):655-65. [MEDLINE: 24643636]
171. Solak Y, Atalay H, Kan S, Kilinc M, Bodur S, Turk S. Effects of vardenafil and sildenafil on sleep quality and depression in impotent hemodialysis patients: a prospective cross-over study [abstract no: SA595]. NDT Plus 2010;3(Suppl 3):iii242-3. [EMBASE: 70484061]
172. Mehrotra R. ASCEND: A trial of sertraline vs. CBT for end-stage renal disease patients with depression. www.clinicaltrials.gov/ct2/show/NCT02358343 (accessed 20 January 2016).
173. Jassal V. Pilot study to evaluate the feasibility and safety of performing a double blind, placebo-controlled, randomized controlled trial of the routine use of SSRI's at the initiation of end-stage renal disease treatment Escitalopram. www.clinicaltrials.gov/ct2/show/NCT02407821 (accessed 20 January 2016).
174. Abbas Tavallaii S, Ebrahimnia M, Shamspour N, Assari S. Effect of depression on health care utilization in patients with end-stage renal disease treated with hemodialysis. European Journal of Internal Medicine 2009;20(4):411-4. [MEDLINE: 19524185]
175. Abram HS, Moore GL, Westervelt FB Jr. Suicidal behavior in chronic dialysis patients. American Journal of Psychiatry 1971;127(9):1199-204. [MEDLINE: 5100612]
176. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24(6):1069-78. [MEDLINE: 11375373]
177. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Archives of Internal Medicine 2000;160(14):2101-7. [MEDLINE: 10904452]
178. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375(9709):132-40. [MEDLINE: 20031199]
179. Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation 2012;27(10):3736-45. [MEDLINE: 22859791]
180. Friend R, Hatchett L, Wadhwa NK, Suh H. Serum albumin and depression in end-stage renal disease. Advances in Peritoneal Dialysis 1997;13:155-7. [MEDLINE: 9360672]
181. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: 18436948]
182. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64(4):380-2. [MEDLINE: 21185693]
183. Haenel T, Brunner F, Battegay R. Renal dialysis and suicide: occurrence in Switzerland and in Europe. Comprehensive Psychiatry 1980;21(2):140-5. [MEDLINE: 6991206]
184. Hedayati SS, Grambow SC, Szczech LA, Stechuchak KM, Allen AS, Bosworth HB. Physician-diagnosed depression as a correlate of hospitalizations in patients receiving long-term hemodialysis. American Journal of Kidney Diseases 2005;46(4):642-9. [MEDLINE: 16183419]
185. Hedayati SS, Yalamanchili V, Finkelstein FO. A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. Kidney International 2012;81(3):247-55. [MEDLINE: 22012131]
186. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
187. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
188. Juergensen PH, Juergensen DM, Wuerth DB, Finkelstein SH, Steele TE, Kliger AS, et al. Psychosocial factors and incidence of peritonitis. Advances in Peritoneal Dialysis 1996;12:196-8. [MEDLINE: 8865901]
189. Kimmel PL, Thamer M, Richard CM, Ray NF. Psychiatric illness in patients with end-stage renal disease. American Journal of Medicine 1998;105(3):214-21. [MEDLINE: 9753024]
190. Koo JR, Yoon JW, Kim SG, Lee YK, Oh KH, Kim GH, et al. Association of depression with malnutrition in chronic hemodialysis patients. American Journal of Kidney Diseases 2003;41(5):1037-42. [MEDLINE: 12722038]
191. Lacson E Jr, Li NC, Guerra-Dean S, Lazarus M, Hakim R, Finkelstein FO. Depressive symptoms associate with high mortality risk and dialysis withdrawal in incident hemodialysis patients. Nephrology Dialysis Transplantation 2012;27(7):2921-8. [MEDLINE: 22273670]
192. Lopes AA, Bragg J, Young E, Goodkin D, Mapes D, Combe C, et al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney International 2002;62(1):199-207. [MEDLINE: 12081579]
193. Manns B, Hemmelgran B, Lillie E, Dip SC, Cyr A, Gladish M, et al. Setting research priorities for patients on or nearing dialysis. Clinical Journal of The American Society of Nephrology: CJASN 2014;9(10):1813-21. [MEDLINE: 24832095]
194. Martin CR, Thompson DR. Prediction of quality of life in patients with end-stage renal disease. British Journal of Health Psychology 2000;5(1):41-55. [EMBASE: 2000060174]
195. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncology 2001;12(2):160-74. [MEDLINE: 21251875]
196. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Advances in Chronic Kidney Disease 2007;14(1):82-99. [MEDLINE: 17200048]
197. O'Connor EA, Whitlock EP, Beil TL, Gaynes BN. Screening for depression in adult patients in primary care settings: a systematic evidence review. Annals of Internal Medicine 2009;151(11):793-803. [MEDLINE: 19949145]
198. Palmer S, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney International 2013;84(1):179-91. [MEDLINE: 23486521]
199. Palmer SC, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, et al. Association between depression and death in people with CKD: a meta-analysis of cohort studies. American Journal of Kidney Diseases 2013;62(3):493-505. [MEDLINE: 23623139]
200. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
201. Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
202. Sensky T, Leger C, Gilmour S. Psychosocial and cognitive factors associated with adherence to dietary and fluid restriction regimens by people on chronic haemodialysis. Psychotherapy & Psychosomatics 1996;65(1):36-42. [MEDLINE: 8838695]
203. Steele TE, Baltimore D, Finkelstein SH, Jeurgenson P, Kliger AS, Finkelstein FO. Quality of life in peritoneal dialysis patients. Journal of Nervous & Mental Disease 1996;184(6):368-74. [MEDLINE: 8642387]
204. Tong A, Sainsbury P, Carter SM, Hall B, Harris DC, Walker RG, et al. Patients' priorities for health research: focus group study of patients with chronic kidney disease. Nephrology Dialysis Transplantation 2008;23(10):3206-14. [MEDLINE: 18445638]
205. Tsay SL, Healstead M. Self-care self-efficacy, depression, and quality of life among patients receiving hemodialysis in Taiwan. International Journal of Nursing Studies 2002;39(3):245-51. [MEDLINE: 11864647]
206. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 2008;358(3):252-60. [MEDLINE: 18199864]
207. Vaccarino V, Johnson BD, Sheps DS, Reis SE, Kelsey SF, Bittner V, et al. Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung, and Blood Institute-sponsored WISE study. Journal of the American College of Cardiology 2007;50(21):2044-50. [MEDLINE: 18021871]
208. Rabindranath KS, Macleod AM, Daly C, Roderick P, Butler J, Wallace S. Physical measures for treating depression in dialysis patients. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD004541]
209. Rabindranath KS, Butler J, Roderick PJ, Wallace SA, Daly C, MacLeod AM. Physical measures for treating depression in dialysis patients. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD004541.pub2]